Bortezomib-D8 (Major)

CAS: 179324-69-7

Ref. TR-B675702

Produktinformation

• Name: Bortezomib-D8 (Major)
• Synonyme: Velcade-D8, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic Acid-D8
• Marke: TRC
• Beschreibung: Applications Labelled Bortezomib, which the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.d6-3%d7-10%d8-86% Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the packageReferences Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005)

Chemische Eigenschaften

• Molekulargewicht: 392.29
• Formel: C₁₉H₁₇D₈BN₄O₄
• Farbe/Form: Off-White
• InChl: InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15?,17-/m0/s1/i3D,4D,5D,6D,7D,11D2,15D
• InChI Key: InChIKey=GXJABQQUPOEUTA-CXLUSBQQSA-N
• SMILES: [2H]c1c([2H])c([2H])c(C([2H])([2H])C([2H])(NC(=O)c2cnccn2)C(=O)N[C@@H](CC(C)C)B(O)O)c([2H])c1[2H]